ProMetic Launches Phase II of Anti-Fibrotic PBI-4050

Author: ProMetic
Date Published: March-2016
Source: ProMetic

ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (“ProMetic” or the “Corporation”) today announced that it will be initiating a double-blind, placebo-controlled phase 2 clinical trial in patients suffering from scleroderma. There is no cure for scleroderma, a chronic disorder characterized by an overproduction of collagen and abnormal growth of connective tissue. This collagen accumulation causes scarring (fibrosis) of the skin, and in the case of systemic scleroderma, also affects internal organs such as the lungs, the kidneys and gastrointestinal system. Scleroderma affects approximately 300,000 individuals in North America alone and varies in severity.